Effects of Glycemic Control and Hypoglycemia on Thrombus Formation Assessed Using Automated Microchip Flow Chamber System: an Exploratory Observational Study

Overview

Journal Thromb J

Publisher Biomed Central

Date 2019 Sep 10

PMID 31496922

Citations 12

Authors

Kiyoaki Yamamoto

Takashi Ito

Tomoka Nagasato

Atsushi Shinnakasu

Mihoko Kurano

Aiko Arimura

Hiroshi Arimura

Hiroshi Hashiguchi

Takahisa Deguchi

Ikuro Maruyama

Yoshihiko Nishio

Affiliations

Soon will be listed here.

Abstract

Background: Thrombus formation is an important factor affecting cardiovascular events and venous thromboembolism in type 2 diabetes. However, it is unclear whether glycemic control reduces thrombogenicity. We investigated the effect of short-term glycemic control (STUDY 1) and hypoglycemia (STUDY 2) on thrombus formation using an automated microchip flow chamber system.

Methods: For STUDY 1, we recruited 10 patients with type 2 diabetes. Before and after 2 weeks of treatment, blood glucose was analyzed with a continuous glucose monitoring system, and thrombogenicity was analyzed with an automated microchip flow chamber system. For STUDY 2, we recruited 10 subjects without diabetes who underwent an insulin tolerance test. We evaluated the change in thrombogenic potential with hypoglycemia.

Results: STUDY1: The mean blood glucose level reduced from 10.1 ± 2.6 to 6.9 ± 0.97 mM ( < 0.01). T10, an indicator of thrombogenicity, significantly attenuated after glycemic control (338 ± 65 vs. 425 ± 117 s, < 0.05). The attenuation in T10 was significantly correlated with changes in mean blood glucose level after treatment ( = - 0.718, < 0.05). STUDY 2: Platelet function was enhanced with decreasing blood glucose; increased platelet function was strongly correlated with an increase in epinephrine.

Conclusions: We demonstrated attenuation in thrombogenicity with short-term comprehensive diabetes care and enhancement in thrombogenicity with hypoglycemia, using a new flow chamber system.

Trial Registration: UMIN-CTR UMIN 000019899, registered 26-Jan-2015 (STUDY 2).

Citing Articles

Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers.

Nandakumar M, Sathyapalan T, Atkin S, Butler A Biomedicines. 2024; 12(6).

PMID: 38927344 PMC: 11201283. DOI: 10.3390/biomedicines12061137.

The impact of triglyceride glucose-body mass index on all-cause and cardiovascular mortality in elderly patients with diabetes mellitus: evidence from NHANES 2007-2016.

Ding L, Fu B, Zhang H, Dai C, Zhang A, Yu F BMC Geriatr. 2024; 24(1):356.

PMID: 38649828 PMC: 11034154. DOI: 10.1186/s12877-024-04992-5.

The prognostic value of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with diabetes or prediabetes: insights from NHANES 2005-2018.

Ding L, Zhang H, Dai C, Zhang A, Yu F, Mi L Cardiovasc Diabetol. 2024; 23(1):84.

PMID: 38419029 PMC: 10902955. DOI: 10.1186/s12933-024-02172-8.

T-TAS 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion.

Samanbar S, Pineyroa J, Moreno-Castano A, Pino M, Torramade-Moix S, Martinez-Sanchez J Blood Transfus. 2023; 22(2):166-175.

PMID: 38063791 PMC: 10920067. DOI: 10.2450/BloodTransfus.550.

Acute severe hypoglycemia alters mouse brain microvascular proteome.

Sakamuri S, Sure V, Oruganti L, Wisen W, Chandra P, Liu N J Cereb Blood Flow Metab. 2023; 44(4):556-572.

PMID: 37944245 PMC: 10981402. DOI: 10.1177/0271678X231212961.

References

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

Osende J, Badimon J, Fuster V, Herson P, Rabito P, Vidhun R . Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 2001; 38(5):1307-12. DOI: 10.1016/s0735-1097(01)01555-8. View

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359(9323):2072-7. DOI: 10.1016/S0140-6736(02)08905-5. View

Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P . Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes. 2003; 52(7):1851-6. DOI: 10.2337/diabetes.52.7.1851. View

Colwell J, Nesto R . The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003; 26(7):2181-8. DOI: 10.2337/diacare.26.7.2181. View

Dunn E, Ariens R, Grant P . The influence of type 2 diabetes on fibrin structure and function. Diabetologia. 2005; 48(6):1198-206. DOI: 10.1007/s00125-005-1742-2. View

Gawaz M, Langer H, May A . Platelets in inflammation and atherogenesis. J Clin Invest. 2005; 115(12):3378-84. PMC: 1297269. DOI: 10.1172/JCI27196. View

Seljeflot I, Larsen J, Dahl-Jorgensen K, Hanssen K, Arnesen H . Fibrinolytic activity is highly influenced by long-term glycemic control in Type 1 diabetic patients. J Thromb Haemost. 2006; 4(3):686-8. DOI: 10.1111/j.1538-7836.2006.01803.x. View

Derosa G, DAngelo A, Ragonesi P, Ciccarelli L, Piccinni M, Pricolo F . Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. J Int Med Res. 2006; 34(5):545-55. DOI: 10.1177/147323000603400513. View

10.

Boden G, Vaidyula V, Homko C, Cheung P, Rao A . Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab. 2007; 92(11):4352-8. DOI: 10.1210/jc.2007-0933. View

11.

Pieters M, Covic N, van der Westhuizen F, Nagaswami C, Baras Y, Loots D . Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model. Thromb Haemost. 2008; 99(4):691-700. PMC: 2854507. DOI: 10.1160/TH07-11-0699. View

12.

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

13.

Furie B, Furie B . Mechanisms of thrombus formation. N Engl J Med. 2008; 359(9):938-49. DOI: 10.1056/NEJMra0801082. View

14.

Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N . Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300(18):2134-41. DOI: 10.1001/jama.2008.623. View

15.

Sam S, Haffner S, Davidson M, DAgostino Sr R, Feinstein S, Kondos G . Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009; 32(5):932-7. PMC: 2671130. DOI: 10.2337/dc08-1856. View

16.

Raz I, Wilson P, Strojek K, Kowalska I, Bozikov V, Gitt A . Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care. 2009; 32(3):381-6. PMC: 2646013. DOI: 10.2337/dc08-1671. View

17.

Schneider D . Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009; 32(4):525-7. PMC: 2660482. DOI: 10.2337/dc08-1865. View

18.

Konya H, Hasegawa Y, Hamaguchi T, Satani K, Umehara A, Katsuno T . Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus. Metabolism. 2010; 59(9):1294-9. DOI: 10.1016/j.metabol.2009.12.004. View

19.

De Caterina R, Madonna R, Sourij H, Wascher T . Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur Heart J. 2010; 31(13):1557-64. DOI: 10.1093/eurheartj/ehq162. View

20.

Sarwar N, Gao P, Kondapally Seshasai S, Gobin R, Kaptoge S, Di Angelantonio E . Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733):2215-22. PMC: 2904878. DOI: 10.1016/S0140-6736(10)60484-9. View